Search This Blog

Wednesday, January 8, 2020

FDA accepts Nabriva’s refiled Contepo application; shares up after hours

The FDA accepts for review Nabriva Therapeutics’ (NASDAQ:NBRV) resubmitted marketing application for Contepo (fosfomycin) for the treatment of complicated urinary tract infections. The agency’s action date is June 19.
The company received a CRL last year citing deficiencies at one of its contract manufacturers.
Shares up 8% after hours.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)